A global leader in biological solutions, this company specializes in enzyme and microbial technologies for industries ranging from agriculture to household care. Investors monitor its performance due to its dominant position in bioinnovation and sustainability-driven product lines.
4 members of Congress have disclosed 14 trades in Novozymes A/S (NVZMY), a Basic Materials company. The buy/sell breakdown shows 8 purchases versus 6 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-10-16 | Josh Gottheimer | buy | $1K – $15K |
| 2023-09-15 | Josh Gottheimer | sell | $1K – $15K |
| 2021-02-17 | Peter Meijer | sell | $1K – $15K |
| 2020-08-04 | Greg Gianforte | sell | $15K – $50K |
| 2020-03-18 | Greg Gianforte | buy | $1K – $15K |
| 2020-01-13 | Greg Gianforte | buy | $15K – $50K |
| 2019-10-11 | Greg Gianforte | buy | $50K – $100K |
| 2019-09-10 | Greg Gianforte | sell | $100K – $250K |
| 2019-06-24 | Donna Shalala | sell | $1K – $15K |
| 2018-12-21 | Greg Gianforte | buy | $100K – $250K |
| 2018-11-20 | Greg Gianforte | sell | $100K – $250K |
| 2018-10-11 | Josh Gottheimer | buy | $1K – $15K |
| 2018-03-20 | Greg Gianforte | buy | $100K – $250K |
| 2018-03-16 | Josh Gottheimer | buy | $1K – $15K |